Previous studies have demonstrated that amyloid precursor protein (APP) can bind and reduce Cu(II) to Cu(I), leading to oxidative modification of APP. In the present study we show that adding copper to Chinese-hamster ovary (CHO) cells greatly reduced the levels of amyloid Aβ peptide (Aβ) both in parental CHO-K1 and in copper-resistant CHO-CUR3 cells, which have lower intracellular copper levels. Copper also caused an increase in the secretion of the APP ectodomain, indicating that the large decrease in Aβ release was not due to a general inhibition in protein secretion. There was an increase in intracellular fulllength APP levels which paralleled the decrease in Aβ generation, suggesting the existence of two distinct regulating mechanisms, one acting on Aβ production and the other on APP synthesis.
INTRODUCTION
Amyloid Aβ peptide (Aβ, βA4), the principal constituent of senile plaques and cerebrovascular amyloid [1, 2] of Alzheimer's disease (AD), is proteolytically derived by consecutive cleavage of β-secretase and γ-secretase from the larger integral membrane amyloid precursor protein (APP), the major isoforms of which contain 695, 751 and 770 residues respectively. APP processing within the Aβ domain by α-secretase precludes amyloid form-ions [8] . Regarding the latter, APP interacts specifically with Zn(II) and Cu(II) at two distinct sites [9, 10] .
Regulation of APP secretion has been characterized in a wide variety of cell lines [11, 12] and, under some circumstances, the rate of Aβ formation was inversely coupled to the rate of sAPP secretion [12] [13] [14] [15] [16] [17] [18] [19] [20] . Activation of certain signal-transduction pathways increases α-secretase cleavage, and some factors can regulate Aβ production, including calcium, oestrogen and cholesterol [14, [21] [22] [23] [24] [25] [26] . Mutations within or flanking the Aβ region and mutations in the presenilin 1 and presenilin 2 genes increase the extracellular concentration of the longer more amyloidogenic Aβ peptide species [27, 28] .
As a possible treatment for AD it would be highly desirable to develop a drug with specific high-affinity binding to APP. One major requirement would be that these ligands should be able to interfere with amyloidogenic APP processing in i o. Of the known APP ligands it has been shown that Zn(II) increases the levels of membrane-associated APP and decreases secretory APP forms in i o [29] . APP also binds Cu(II), and this leads to oxidation of APP in itro [30] [31] [32] . Furthermore, Cu(II) binding causes conformational changes in APP [10] , and this can modulate APP-APP interactions [33] . This encouraged us to examine the regulation of APP processing by Cu(II). To study this we used normal Chinese-hamster ovary (CHO) cells and a Cu(II)-resistant variant of CHO cells (CUR3). The Cu(II) resistance of CUR3 cells is due to the maintenance of lower intracellular Cu(I) in the presence of elevated extracellular Cu(II) as a consequence of enhanced copper efflux resulting from overexpression of the Menkes P-type ATPase Cu-translocating pump [34] . Treatment of these cells with Cu(II) increased the secretion of C-terminal truncated APP and decreased Aβ release into the conditioned medium (CM) in a concentration-dependent manner. This suggests that Cu(II) binding of intracellular APP attenuates Aβ production and at the same time fosters the generation of secretory APP.
EXPERIMENTAL Cell lines and transfections
CHO cells were stably transfected with a c-Myc-tagged APP695 vector [35] or the expression vector alone using a high-efficiency calcium phosphate transfection method [36] . The pSP65 N-tag APP695 DNA was cloned into the pcDNA3 vector (Invitrogen\ ITC Biotechnology, Heidelberg, Germany) using the cloning sites SmaI and EcoRV respectively.
Transfection efficiency was assessed by immunoprecipitation of APP with rabbit polyclonal anti-c-Myc antibody (18\47, raised against EQKLISEEDL of the c-Myc sequence by Eurogentec, Seraing, Belgium) and immunoblotting using the anti-APP mouse monoclonal antibody 22C11 (Boehringer, Mannheim, Germany) in the ECL2 (enhanced chemiluminescence) detection system (Amersham, Braunschweig, Germany).
Parental CHO-K1 and Cu(II)-resistant variant CUR3 cells [34] were grown at 37 mC in basal Eagle's Medium (BME) supplemented with 2 mM -glutamine, 0.1 mM proline, 20 mM Hepes and 10 % (v\v) fetal-calf serum (Boehringer, Ingelheim, Germany). The basal Cu(II) concentration of BME is 0.8 µM [34] . CUR3 cells were grown in medium containing 200 µM added Cu(II) until the cells reached a 70 % confluent monolayer. This reflects the minimal Cu(II) level that is necessary for CUR3 cells to maintain the 70-fold elevated level of the Menkes P-type ATPase Cu-translocating pump and to ensure that the CUR3 cells are viable in the presence of elevated Cu(II) concentrations.
Metabolic labelling and immunoprecipitation
Stably transfected CHO cells of a 60 mm-diameter culture dish were washed with PBS and then treated with 2 ml of minimum essential medium (MEM) lacking methionine (Sigma, Mu$ nchen, Germany) to allow a ' reset ' of growing conditions regarding the various Cu(II) levels in media of CHO-K1 and CHO-CUR3 cells during culturing. Labelling was performed in 2 ml of MEM, supplemented with 220 µCi of [$&S]methionine (Amersham) and 5 % CO # for 4 h. CM and cells were harvested and immunoprecipitated. Protein concentrations were assayed by using a Bio-Rad Protein Assay [37] or radiolabelled proteins were precipitated in 10 % (w\v) trichloroacetic acid and the incorporated [$&S]methionine label (Beckman LS 6000IC) was measured.
Cells were lysed in an extraction buffer containing 50 mM Tris\HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 % Triton X-100, 2 % (v\v) Nonidet P40, 1 mM PMSF, 10 µg\ml aprotinin and 10 µg\ml leupeptin. The lysate and the medium were centrifuged for 10 min at 13 000 g to remove cellular debris and the medium was adjusted to 25 mM Tris\HCl (pH 8.5)\1 mM PMSF\10 µg\ml aprotinin\10 µg\ml leupeptin\0.5 % Triton X-100\0.5 % Nonidet P40. The solubilized proteins were diluted 1 : 2 in 100 mM Tris\HCl (pH 7.5)\300 mM NaCl\4 mM EDTA. The supernatants were incubated with anti-APP antibodies overnight by end-over-end rotation at 4 mC and, in some experiments, the resulting supernatant was subsequently analysed with anti-Aβ antiserum. Immune complexes were recovered with Protein A-Sepharose and subjected to the analysis described in [38] .
Antibodies and electrophoresis
For the detection of APP, rabbit polyclonal antibodies that were raised against recombinant Fd-APP770 (antiserum 22734\8 against APP770 residues 18-687 or antiserum 23850\6 against APP residues 18-491 ( Figure 1 ) were diluted 1 : 500 for precipitation. Aβ, p3.5 and p3 were recognized by the polyclonal antibody 730 (dilution 1 : 50) precipitating equally Aβ, p3.5 and p3 that was raised against a synthetic peptide corresponding to Aβ residues 1-40 ( Figure 1 ). Aβ and its derivatives were separated by 10-20 %-polyacrylamide\Tris\Tricine, APP by 7 %-polyacrylamide\Tris\glycine or 7 %-polyacrylamide\Tris\ Tricine gels. For immunoblotting, cell extracts and extracellular medium were precipitated in 10 % trichloroacetic acid, washed with acetone and solubilized in sample buffer. After electrophoresis the gels were processed as described in [39] and bands quantified with the Fuji-Bas PhosphorImager system. Data are representative of at least two separate trials.
Drug treatments and lactate dehydrogenase (LDH) assay
During the time of labelling, Cu(II) or Zn(II) chloride was added to growth medium at concentrations of 5 µM-200 µM; -(k)-penicillamine (PEN ; Sigma), bathocuproine disulphonate (BC ; Aldrich) and 1,10-phenanthroline (Sigma) were added to medium to give final concentrations of 100 µM (PEN and BC) and 200 µM (1,10-phenanthroline) respectively. Cell viability was measured by assaying LDH leakage into the culture medium [40] . The leakage was measured as enzyme activity (units\litre) after 2 and 4 h in the medium of 70 % confluent monolayers of CHO cells in Dulbecco's modified Eagle's medium (DMEM).
RESULTS
The parental CHO-K1 and the Cu(II)-resistant variant CUR3 cell lines were used to study the role of Cu(II) on APP processing [34, 41] .
CHO-K1 and CUR3 cells were stably transfected with cDNAs encoding APP695 with an N-terminal c-Myc epitope (Figure 1 ). APP expression was detected by immunoprecipitation with polyclonal anti-c-Myc antiserum, followed by immunoblotting with monoclonal antibody 22C11 (Figures 2a and 2b) . The polyclonal anti-c-Myc antibody immunoprecipitated c-Myctagged APP695 with an apparent molecular mass of 105 kDa from the cell lysate (cAPP) and 105 and 97.5 kDa from the CM (sAPP). As expected, c-Myc-APP695 was detected in neither the lysate nor the medium of cells stably transfected with pcDNA3 alone (Figures 2a and 2b) .
To analyse the regulation of APP metabolism by Cu(II) ions, stably transfected CUR3-APP695 cells were labelled for 4 h with [$&S]methionine in the presence of different Cu(II) levels and the secretion of APP ectodomain, Aβ and p3 were analysed by immunoprecipitation and SDS\PAGE in a Tris\Tricine\ polyacrylamide gel system. This allowed the quantification of APP and its derivatives on the same gel. Cell lysates of CUR3-APP695 cells revealed the 105 kDa immature cAPP695 holoprotein (Figure 3a) . APP695 derivatives released into CM were detected as bands of 105 and 97.5 kDa (Figure 3b ), most likely differing from each other by a higher content of sialic acids in the upper band [39] . The cell lines did not show a decrease in viability as measured by LDH release.
The levels of APP holoprotein and soluble APP increased significantly when CUR3-APP695 cells were incubated with increasing concentrations of Cu(II). Compared with basal medium the maximum increase in sAPP occured at 50 µM Cu(II) (265p15 % increase) before a general increase in total cellular secreted proteins occured (Figures 3c, 3e and 3f ). Immunoprecipitation of radiolabelled peptides derived from the Aβ region of APP was achieved with rabbit antiserum 730, which recognized Aβ (4.5 kDa), p3.5 (3.5 kDa) and p3 (3 kDa) ( Figure  1) . Secretion of p3, the C-terminal counterpart to secretory APP produced by α-secretase cleavage, increased by 204p14 % at 50 µM Cu(II) (Figures 3d, 3e and 3f ) in the medium, reaching a maximum of 270p14 % between 20 µM and 50 µM Cu(II) (Figures 3d and 3e) . The percentage of cAPP was markedly increased by 205p3.5 % at 50 µM Cu(II) (Figures 3a, 3c and 3f) . When Cu(II) concentrations exceeded 50 µM in the medium, the general protein metabolism of cells was affected and cAPP levels increased further (Figures 3a and 3c) . In contrast, Aβ levels were greatly reduced at 50 µM Cu(II) (20p1.4 % of basal levels ; Figures 3d, 3e and 3f) and Aβ was barely detectable above 100 µM in CUR3-APP695 cells (Figures 3d and 3e) . The p3.5 peptide showed a similar pattern (Figure 3d ) and confirmed an earlier finding that p3.5 is the product of an alternative β-secretase activity [39] . The polyclonal Aβ antiserum 730 and a monoclonal antibody recognizing Aβ40 specifically precipitated equal amounts of Aβ (results not shown).
To determine if cellular APP, sAPP and downstream catabolites are also modulated by a decrease in Cu(II) levels, CUR3-APP cells were incubated with the Cu(II) chelators PEN and BC, a cell non-permeable Cu(I) chelator. It was found that the production of Aβ and p3.5 was unaffected, whereas sAPP and p3 were reduced to 77p1.6 % and 50p1. In CHO-K1-APP695 cells the levels of APP [cAPP 295p9.9 % and sAPP695 475p66.1 % at 10 µM Cu(II)] and p3 [154p7.0 % at 10 µM Cu(II)] were significantly increased when incubated with increasing Cu(II) concentrations (Figures 4a-4f) . However, the production of Aβ decreased to 33p1.3 % at 10 µM Cu(II) (Figures 4d-4f ) and was undetectable beyond 20 µM (Figures  4d-4e ). In the presence of BC\PEN, sAPP695 secretion was increased by 170p7.5 % (Figure 4 , lane BC\PEN in b, data point ' 0 ' in c) and p3 secretion was 171p5.8 % (Figure 4 , lane BC\PEN in d, data point ' 0 ' in e), but no change in the level of Aβ was observed (Figures 4d-4e) .
In contrast with CUR3-APP695 cells, the maximum rate of APP secretion of CHO-K1-APP695 cells was reached at 10 µM Cu(II) for sAPP695 (Figures 4b, 4c , 4e and 4f) and then decreased at Cu(II) concentrations between 20 µM and 200 µM ( Figures  4b, 4c and 4e ). There was a general increase in secreted proteins at concentrations greater than 20 µM (Figure 4c The doublet appearance of sAPP695 (b), restricted to higher Cu(II) concentrations is due to its different sialic acid content [39] . A fragment that migrates just above the Aβ band (d) is detected at low levels and is presumably generated by δ-and γ-secretase activity [39] (see Figure 1) Comparison of APP secretion with p3 secretion showed that increases in APP and p3 secretion occurred concomitantly, suggesting that APP is released by α-secretase activity as sAPPα (Figures 5a and 5b) . The decrease in Aβ production from CHO-K1-APP695 and CHO-CUR3-APP695 cells did not appear to be related to the increase in APP secretion (Figures 5a and 5b) , leading to the conclusion that different mechanisms are involved.
DISCUSSION
The CHO model system was chosen to study the effects of Cu(II) on APP processing because of the ability of modulating extracellular Cu(II) levels to influence intracellular Cu(I) [34, 42] . Previous studies revealed a reduced intracellular Cu(II)\(I) accumulation due to enhanced Cu(I) efflux as the molecular basis of Cu(II) resistance in CHO-CUR3 cells [34, 42] . In contrast with the CHO-CUR3 cells, the parental line CHO-K1 has normal intracellular Cu(II)\(I) levels, since it was not selected for Cu(II) resistance or overexpression of Menkes active P-type ATPase, which is a transmembrane Cu-translocating pump [34] . We measured a specific effect of Cu(II) on the secretion of sAPP, the production of APP and Aβ release that was dependent on the concentration of Cu(II) and the degree of cellular Cu(II) resistance. Maximal inhibition of Aβ production and stimulation of APP secretion was achieved in CHO-K1-APP695 cells at about 10 µM copper and in CHO-CUR3-APP695 cells at about 50 µM copper. The addition of Cu(II) to the medium results in an increase of the release of the APP products sAPP and p3 of the α-secretory pathway and a decrease in the release of the β-secretase products Aβ and p3.5. Cleavage by γ-secretase, which is required to generate the C-terminus of p3, did not appear to be inhibited by increasing Cu(II) concentrations. Unfortunately we were unable to determine if the ratio of Aβ42 to Aβ40 is influenced by increasing Cu(II) concentrations, owing to two superimposing factors : the total amount of Aβ produced decreases under the given conditions and the affinity of the monoclonal antibody recognizing Aβ42 is insufficient. The increase in sAPP and p3 secretion by elevated Cu(II) concentrations in both cell lines is accompanied by a concomitant increase in cell-associated full-length APP. This APP pool appears to consist of mainly N-glycosylated endoplasmicreticulum forms of APP [38] , since the N-and O-glycosylated mature forms of APP represent, if at all present, a minor fraction. The presence of this APP pool could indicate that only mature APP is diverted into the pathway leading to constitutive secretion of APP and p3. Alternatively, inhibition of the β-secretase pathway, which leads to Aβ production by Cu(II), may occur in a cellular compartment from which APP cannot reach the constitutive α-secretory-vesicle system. This suggests that two pools of APP could exist : one for secretory APP and p3 and another for Aβ production.
The recent association of an α-secretase activity with a Zn(II) disintegrin metalloprotease [43] does not explain our results. First, Zn(II) did not give the same results as found for Cu(II). Secondly, at least in CHO-K1-APP695 cells, APP and p3 were found to be slightly increased in the presence of Cu(I) and Zn(II) chelators (Figure 4 ). Thirdly, a general increase in ectodomain shedding by activation of any potential metalloprotease due to elevated Cu(II) concentration has not been observed when the specific increase of sAPP and p3 in the dose ' window of opportunity ' was recorded.
On the basis of the different Cu(II) concentrations required to inhibit completely Aβ production in the two cell lines used in the present study, we conclude that Cu(II) has to be internalized before it can exert its effect on APP metabolism. The arguments are as follows. The Cu(II)-resistant CHO cell line CHO-CUR3 requires five times higher extracellular Cu(II) concentrations to achieve the same diminution of Aβ secretion as the CHO-K1 cells. This is due to the 70-fold elevated expression of the Menkes P-type ATPase [34] , leading to significantly reduced intracellular Cu(I) levels in CUR3 cells. Therefore a 5-fold higher extracellular Cu(II) concentration is required to reach the same intracellular Cu(II) levels as in CHO-K1 cells. Otherwise it is difficult to conceive how a 5-fold difference could influence APP metabolism, since the binding constant for Cu(II) of APP exposed to the cell surface should be identical for APP in K1-APP695 and CUR3-APP695 cells.
How could intracellular Cu(II)\(I) interfere with APP processing ? Since Cu(II) binding to APP is known to cause a conformational change, this could facilitate α-cleavage and attenuate β-cleavage. It was recently shown that β-cleavage depends on the transport of APP to lipid rafts enriched in cholesterol [25] . Therefore APP-Cu(II) complexes could be compromised in this transport and, as a consequence, not reach the compartment in which the β-secretase resides.
Our findings of the inhibition of the amyloidogenic pathway by Cu(II) is potentially important for the Alzheimer's-disease treatments aimed at the inhibition of Aβ production. The current approaches are directed at interfering with Aβ generation by compounds that inhibit the hitherto-unidentified β-secretase or γ-secretase [44] . Since these proteases are likely to be involved in processing several transmembrane proteins, their inhibition may have unforeseen consequences for cellular viability. On the basis of our findings, we propose an alternative and more specific approach for the design of Cu(II) agonists which promote the formation of APP complexes and a subsequent attenuation of Aβ metabolism. Since Cu(II) binding by APP also generates highly cytotoxic Cu(I) ions, these agonists would have the additional potential to protect cells from damage by blocking Cu(II) binding of APP and thus preventing the formation of reactive oxygen species produced by Cu(II) and hydrogen peroxide.
In conclusion, the CHO model has proved to be powerful in elucidating the modulating effect of Cu(II) on APP processing. Further studies will be directed to investigating this effect in neuronal cells to see whether our results can be generalized.
